PT - JOURNAL ARTICLE AU - Lausberg, Eva AU - Gießelmann, Sebastian AU - Dewulf, Joseph P AU - Wiame, Elsa AU - Holz, Anja AU - Salvarinova, Ramona AU - Karnebeek, Clara Van AU - Klemm, Patricia AU - Ohl, Kim AU - Mull, Michael AU - Braunschweig, Till AU - Weis, Joachim AU - Sommer, Clemens AU - Demuth, Stephanie AU - Haase, Claudia AU - Debray, François-Guillaume AU - Libioulle, Cecile AU - Choukair, Daniela AU - Oommen, Prasad T. AU - Borkhardt, Arndt AU - Surowy, Harald AU - Wieczorek, Dagmar AU - Meyer, Robert AU - Eggermann, Thomas AU - Begemann, Matthias AU - Schaftingen, Emile Van AU - Häusler, Martin AU - Tenbrock, Klaus AU - den Heuvel, Lambert van AU - Elbracht, Miriam AU - Kurth, Ingo AU - Kraft, Florian TI - A human multisystem disorder with autoinflammation, leukoencephalopathy and hepatopathy is caused by mutations in <em>C2orf69</em> AID - 10.1101/2021.03.08.21252805 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.08.21252805 4099 - http://medrxiv.org/content/early/2021/03/12/2021.03.08.21252805.short 4100 - http://medrxiv.org/content/early/2021/03/12/2021.03.08.21252805.full AB - Background Deciphering the function of the many genes previously classified as uncharacterized “open reading frame” (orf) completes our understanding of cell function and its pathophysiology.Methods Whole-exome sequencing, yeast 2-hybrid and transcriptome analyses together with molecular characterization are used here to uncover the function of the C2orf69 gene.Results We identify loss-of-function mutations in the uncharacterized C2orf69 gene in eight individuals with brain abnormalities involving hypomyelination and microcephaly, liver dysfunction and recurrent autoinflammation. C2orf69 contains an N-terminal signal peptide that is required and sufficient for mitochondrial localization. Consistent with mitochondrial dysfunction, patients show signs of respiratory chain defect and a CRISPR-Cas9 knockout cell model of C2orf69 shows comparable respiratory chain defects. Patient-derived cells reveal alterations in immunological signaling pathways. Deposits of PAS-positive material in tissues from affected individuals together with decreased glycogen branching enzyme 1 (GBE1) activity indicate an additional impact of C2orf69 on glycogen metabolism.Conclusion Our study identifies C2orf69 as an important regulator of human mitochondrial function and suggests an additional influence on other metabolic pathways.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Deutsche Forschungsgemeinschaft (DFG) and Fund Invest for Scientific Research (FIRS) Grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from the parents / legal guardians of the study participants after approval from the Institutional Review Boards at the participating institutions (EK302-16; UK D 4886R; H12-00067, UBC). Consent was obtained according to the Declaration of Helsinki. EK302-16 approved by Ethik-Kommission an der Medizinischen Fakultaet der Rheinisch-Westfaelischen Technischen Hochschule Aachen (RWTH Aachen) Universitaetsklinikum Aachen Pauwelsstrasse 30 52074 Aachen ekaachen{at}ukaachen.de https://www.medizin.rwth-aachen.de/cms/Medizin/Die-Fakultaet/Organisation/~coeq/Ethik-Kommission/ UK D 4886R approved by Ethikkommission an der Med. Fakultaet der HHU Duesseldorf Gebaeude 14.82.01 Moorenstr. 5 40225 Duesseldorf ethikkommission{at}med.uni-duesseldorf.de https://www.medizin.hhu.de/dekanat/gremien-und-kommissionen/kommissionen/ethikkommission.html H12-00067 approved by UBC Clinical Research Ethics Office Room 210, Research Pavilion 828 West 10th Avenue Vancouver, BC Canada V5Z 1L8 pia.ganz{at}ors.ubc.ca https://ethics.research.ubc.ca/clinical-research-ethicsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata is avaiable upon request, if not protected by GDPR